Search

Your search keyword '"Garde E"' showing total 447 results

Search Constraints

Start Over You searched for: Author "Garde E" Remove constraint Author: "Garde E"
447 results on '"Garde E"'

Search Results

1. Universal DNA methylation age across mammalian tissues.

5. Author Correction: Universal DNA methylation age across mammalian tissues

8. ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus

9. Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC

11. Hierarchical structure of the spiralled narwhal tusk studied by X-ray imaging

13. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

14. Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC (BMC Medical Research Methodology, (2023), 23, 1, (1), 10.1186/s12874-022-01760-0)

15. [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial

17. Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC

18. Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC (BMC Medical Research Methodology, (2023), 23, 1, (1), 10.1186/s12874-022-01760-0)

19. Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer

20. [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial

26. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

27. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia

28. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia

29. Community-acquired pneumonia subgroups and differential response to corticosteroids:a secondary analysis of controlled studies

32. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

37. Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC.

41. The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC

42. The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC

43. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

44. Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

45. Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective (BMC Infectious Diseases, (2018), 18, 1, (677), 10.1186/s12879-018-3565-z)

46. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study

47. Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome

48. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

49. Chloroquine-induced QTc prolongation in COVID-19 patients

50. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

Catalog

Books, media, physical & digital resources